In this issue of Blood, Draper et al demonstrate that 2 isoforms of the transcription factor RUNX1, which are generated by alternate promoter usage, play distinct functional roles during megakaryopoiesis. 1 
R
UNX1 is a key hematopoietic and endothelial transcription factor that plays critical roles in definitive hematopoietic stemcell biogenesis and the differentiation of essentially all major hematopoietic lineages except the erythroid lineage. It is particularly important during megakaryopoiesis, where it directly controls the expression of genes involved in megakaryocyte survival and maturation, endomitosis, and platelet formation. Germ line loss-of-function or dominant-negative acting mutations cause an autosomal-dominant syndrome of impaired megakaryocyte maturation, thrombocytopenia, platelet dysfunction, and leukemia predisposition. The RUNX1 gene is also a frequent target of somatic chromosomal rearrangements and point mutations in leukemia and myelodysplastic syndrome.
RUNX1 is normally transcribed from 2 separate promoters: a distal promoter designated P1 and a proximal promoter designated P2. figure) . Likewise, ex vivo culture of purified PreMegEs shows significantly reduced megakaryocytic output with concomitant increased erythroid output. There is also increased late apoptosis of MkPs. However, the mutant MkPs that survive undergo full terminal megakaryocyte maturation. This latter finding contrasts with what is observed in full RUNX1 hematopoietic knockout mice, in which both megakaryocyte lineage commitment and maturation are severely impaired. [4] [5] [6] Collectively, these findings provide strong evidence for a selective requirement of the RUNX1c isoform in cell-fate choice of preMegEs for the megakaryocyte lineage and for survival of early committed MkPs. This is one of the first studies to provide in vivo evidence for the nonequivalency of RUNX1b and RUNX1c during native adult hematopoiesis and strongly suggests that these differences relate to the altered amino terminal amino acid sequences of the 2 isoforms. It will be of interest to further understand the mechanisms that underlie the functional differences of these 2 isoforms. Prior work has demonstrated that RUNX1c has higher DNA binding affinity than RUNX1b. 7 It is therefore possible that differences in chromatin occupancy site usage could account for the different behaviors. It is also possible that differences in proteinprotein interactions, conformation, stability, and/or cell localization could be involved.
The mechanisms that mediate cell-fate choice of preMegEs for the megakaryocyte versus erythroid lineage are just beginning to be elucidated. Prior work has shown that the major megakaryocyte transcription factor FLI1 cross-antagonizes the key erythroid-specific transcription factor KLF1 in this decision and that FLI1 physically and functionally cooperates with RUNX1. 8, 9 Recent work by Kuvardina et al 10 showed that RUNX1 directly represses transcription of the KLF1 gene. Given the findings of Draper et al in the current study, it would be of interest to determine if RUNX1c, but not RUNX1b, is involved in this repressive event.
Draper et al previously showed that RUNX1 expression switches from being predominantly P1 to P2 directed during megakaryocyte maturation. In the current study, they demonstrate that RUNX1b is sufficient to support normal megakaryocyte maturation beyond the MkP stage. It would therefore be of interest to perform the converse experiment to that described in the current study, in which the RUNX1c sequences would be substituted for those of RUNX1b at the P2 promoter. This would determine whether RUNX1b is not only sufficient but also selectively required for terminal megakaryocyte maturation.
The structure of the RUNX1 gene locus, with its dual promoters and isoform-specific transcript products, is highly evolutionarily conserved and also occurs in the 2 other known mammalian RUNX family genes, RUNX2 and RUNX3.
2 These factors play broad roles in normal development. It will be of interest to apply the experimental approach of Draper et al to these other family members and in other cellular contexts to determine whether the functional significance of RUNX alternate promoter usage and isoform specificity is broadly applicable. It also points to the importance of further understanding the factors and signaling events that dictate P1 vs P2 promoter usage. There is considerable interest in generating platelets in vitro from human-induced pluripotent stem cells for ultimate transfusion purposes. However, the extremely low efficiency of platelet generation with current culture systems remains a major obstacle in this field. The work of Draper et al suggests that manipulation of specific RUNX1 isoforms during ex vivo culture could potentially be used to enhance platelet production via skewing of progenitor cell-fate choice toward the megakaryocyte lineage, improving MkP survival and supporting terminal megakaryocyte maturation.
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